Tectonic Therapeutic (TECX) said late Thursday that its lead asset TX45 for the potential treatment of group 2 pulmonary hypertension in heart failure with preserved ejection fraction showed "minimal" adverse events in a phase 1a clinical trial.
TX45 was well-tolerated and showed a "favorable" pharmacokinetic and pharmacodynamic relationship that was used to identify doses for phase 2 clinical trial, the company said.
"These topline phase 1a findings for TX45 validate the preliminary data previously presented at lower doses, and we look forward to sharing the full trial results at the AHA Scientific Sessions later this year," Tectonic Chief Executive Alise Reicin said.
Price: 19.81, Change: +0.01, Percent Change: +0.05
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。